Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma

Beksac, Meral; Aydin, Yildiz; GÖKER, HAKAN; Turgut, Mehmet; BEŞIŞIK, Sevgi; Cagirgan, Seckin; Tuglular, Tulin; VURAL, FİLİZ; Yagci, Munci; Alacacioglu, Inci; Aytan, Pelin; Goksoy, Hasan; Gulbas, Zafer; Gunes, Ahmet; Gurkan, Emel; Hacioglu, Sibel; Karti, Suleyman; Kaynar, Leylagul; Ozdogu, Hakan; Paydas, Semra; Solmaz, Soner; SÖNMEZ, MEHMET; Tekgunduz, Emre; Yildirim, Rahsan; Ilhan, Osman

doi:10.1016/j.clml.2020.02.017

Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma

Copy For Citation

Beksac M., Aydin Y., GÖKER H., Turgut M., BEŞIŞIK S., Cagirgan S., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.20, no.8, 2020 (SCI-Expanded)

Publication Type: Article / Review
Volume: 20 Issue: 8
Publication Date: 2020
Doi Number: 10.1016/j.clml.2020.02.017
Journal Name: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Karadeniz Technical University Affiliated: Yes

Abstract

The present study investigated the efficacy and safety profile of daratumumab monotherapy in 42 patients with relapsed refractory multiple myeloma through a Turkish early access program. The current findings have confirmed the efficacy of daratumumab monotherapy in heavily pretreated patients with refractory multiple myeloma because of the deep and durable responses and favorable safety and tolerability profile.